Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director | |||||
| By: GlobeNewswire - 28 May 2020 | Back to overview list |
||||
Gilles Schnepp has also been appointed as a member of the Audit Committee. A graduate of HEC in 1981, Gilles Schnepp began his career at Merrill Lynch in 1983 before joining Legrand in 1989 where he held several positions before becoming Deputy Chief Executive Officer in 2001, Chief Executive Officer in 2004 and Chairman and Chief Executive Officer in 2006. Since 2018, he has been Chairman of the Board of Directors Gilles Schnepp has also been a member of the Board of Directors of Saint Gobain since 2009 and Vice-Chairman of the Supervisory Board of PSA since 2019. Gilles Schnepp thus brings to the Board his skills in financial matters and his experience in managing international groups. The entire Board of Directors thanked Emmanuel Babeau for his very substantial and active participation in the meetings of the Board and of the Audit Committee of which he was a member. The Board of Directors has 16 members, including 11 who are deemed independent and two Directors representing employees.
About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare Attachment |
|||||
|
|
|||||
 | Back to overview list | ||||